Market Closed -
Nyse
04:00:02 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
770
USD
|
-0.15%
|
|
+1.32%
|
+32.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
126,190
|
153,067
|
250,419
|
347,613
|
524,224
|
693,312
|
-
|
-
|
Enterprise Value (EV)
1 |
139,069
|
165,981
|
263,395
|
361,640
|
546,522
|
713,294
|
708,598
|
702,337
|
P/E ratio
|
14.8
x
|
24.9
x
|
45.1
x
|
53
x
|
101
x
|
57.6
x
|
41.4
x
|
32.2
x
|
Yield
|
1.96%
|
1.75%
|
1.23%
|
1.07%
|
0.78%
|
0.68%
|
0.78%
|
0.86%
|
Capitalization / Revenue
|
5.65
x
|
6.24
x
|
8.84
x
|
12.2
x
|
15.4
x
|
16.1
x
|
13.2
x
|
11.2
x
|
EV / Revenue
|
6.23
x
|
6.76
x
|
9.3
x
|
12.7
x
|
16
x
|
16.6
x
|
13.5
x
|
11.3
x
|
EV / EBITDA
|
18.4
x
|
19.3
x
|
26.3
x
|
38.2
x
|
63.7
x
|
44
x
|
32.6
x
|
25.2
x
|
EV / FCF
|
36.6
x
|
32.5
x
|
44.3
x
|
69.1
x
|
690
x
|
78.8
x
|
50.9
x
|
37.9
x
|
FCF Yield
|
2.73%
|
3.08%
|
2.26%
|
1.45%
|
0.15%
|
1.27%
|
1.96%
|
2.64%
|
Price to Book
|
48.3
x
|
28.6
x
|
29.4
x
|
32.7
x
|
48.9
x
|
38.9
x
|
23.9
x
|
16
x
|
Nbr of stocks (in thousands)
|
960,131
|
906,582
|
906,592
|
950,178
|
899,307
|
900,405
|
-
|
-
|
Reference price
2 |
131.4
|
168.8
|
276.2
|
365.8
|
582.9
|
770.0
|
770.0
|
770.0
|
Announcement Date
|
1/30/20
|
1/29/21
|
2/3/22
|
2/2/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22,320
|
24,540
|
28,318
|
28,541
|
34,124
|
42,999
|
52,614
|
62,148
|
EBITDA
1 |
7,551
|
8,589
|
10,005
|
9,472
|
8,584
|
16,205
|
21,767
|
27,866
|
EBIT
1 |
6,079
|
7,265
|
8,457
|
7,950
|
7,057
|
14,694
|
19,991
|
25,641
|
Operating Margin
|
27.24%
|
29.6%
|
29.86%
|
27.85%
|
20.68%
|
34.17%
|
38%
|
41.26%
|
Earnings before Tax (EBT)
1 |
5,266
|
7,230
|
6,156
|
6,806
|
6,555
|
13,737
|
18,597
|
22,671
|
Net income
1 |
8,318
|
6,194
|
5,582
|
6,245
|
5,240
|
11,932
|
16,553
|
21,400
|
Net margin
|
37.27%
|
25.24%
|
19.71%
|
21.88%
|
15.36%
|
27.75%
|
31.46%
|
34.43%
|
EPS
2 |
8.890
|
6.790
|
6.120
|
6.900
|
5.800
|
13.37
|
18.58
|
23.94
|
Free Cash Flow
1 |
3,803
|
5,112
|
5,951
|
5,230
|
792.5
|
9,050
|
13,912
|
18,540
|
FCF margin
|
17.04%
|
20.83%
|
21.01%
|
18.32%
|
2.32%
|
21.05%
|
26.44%
|
29.83%
|
FCF Conversion (EBITDA)
|
50.36%
|
59.52%
|
59.48%
|
55.21%
|
9.23%
|
55.85%
|
63.91%
|
66.53%
|
FCF Conversion (Net income)
|
45.71%
|
82.53%
|
106.61%
|
83.75%
|
15.12%
|
75.85%
|
84.04%
|
86.64%
|
Dividend per Share
2 |
2.580
|
2.960
|
3.400
|
3.920
|
4.520
|
5.199
|
5.993
|
6.587
|
Announcement Date
|
1/30/20
|
1/29/21
|
2/3/22
|
2/2/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
8,000
|
7,810
|
6,488
|
6,942
|
7,302
|
6,960
|
8,312
|
9,499
|
9,353
|
8,768
|
10,008
|
11,328
|
12,796
|
10,920
|
12,135
|
EBITDA
1 |
2,982
|
3,046
|
1,679
|
2,373
|
2,375
|
1,982
|
2,618
|
986.4
|
2,855
|
3,049
|
3,747
|
4,838
|
5,994
|
-
|
-
|
EBIT
1 |
2,536
|
2,610
|
1,330
|
2,010
|
2,000
|
1,620
|
2,252
|
575.4
|
2,468
|
2,648
|
3,080
|
3,976
|
4,816
|
-
|
-
|
Operating Margin
|
31.7%
|
33.42%
|
20.5%
|
28.96%
|
27.39%
|
23.27%
|
27.09%
|
6.06%
|
26.38%
|
30.2%
|
30.78%
|
35.1%
|
37.63%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
2,089
|
427.2
|
2,509
|
2,536
|
3,000
|
3,878
|
4,496
|
-
|
-
|
Net income
1 |
1,726
|
1,903
|
952.5
|
1,452
|
1,938
|
1,345
|
1,763
|
-57.4
|
2,190
|
2,243
|
2,477
|
3,249
|
4,025
|
-
|
-
|
Net margin
|
21.58%
|
24.36%
|
14.68%
|
20.91%
|
26.54%
|
19.32%
|
21.21%
|
-0.6%
|
23.41%
|
25.58%
|
24.75%
|
28.68%
|
31.46%
|
-
|
-
|
EPS
2 |
1.900
|
-
|
1.050
|
1.610
|
2.140
|
1.490
|
1.950
|
-0.0600
|
2.420
|
2.480
|
2.774
|
3.604
|
4.460
|
-
|
-
|
Dividend per Share
2 |
0.8500
|
0.9800
|
0.9800
|
0.9800
|
0.9800
|
1.130
|
1.130
|
1.130
|
1.130
|
1.300
|
1.300
|
1.300
|
1.299
|
-
|
-
|
Announcement Date
|
2/3/22
|
4/28/22
|
8/4/22
|
11/1/22
|
2/2/23
|
4/27/23
|
8/8/23
|
11/2/23
|
2/6/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
12,879
|
12,914
|
12,976
|
14,027
|
22,298
|
19,982
|
15,286
|
9,024
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.706
x
|
1.504
x
|
1.297
x
|
1.481
x
|
2.598
x
|
1.233
x
|
0.7022
x
|
0.3239
x
|
Free Cash Flow
1 |
3,803
|
5,112
|
5,951
|
5,230
|
793
|
9,050
|
13,912
|
18,540
|
ROE (net income / shareholders' equity)
|
89.6%
|
175%
|
102%
|
73.2%
|
48.9%
|
82.7%
|
73.7%
|
65.6%
|
ROA (Net income/ Total Assets)
|
13.4%
|
14.4%
|
15.6%
|
14.6%
|
9.23%
|
17.6%
|
21.3%
|
24.7%
|
Assets
1 |
62,143
|
42,961
|
35,816
|
42,708
|
56,748
|
67,726
|
77,640
|
86,770
|
Book Value Per Share
2 |
2.720
|
5.900
|
9.410
|
11.20
|
11.90
|
19.80
|
32.20
|
48.20
|
Cash Flow per Share
2 |
5.170
|
7.120
|
7.960
|
7.830
|
4.690
|
15.40
|
20.00
|
25.20
|
Capex
1 |
1,034
|
1,388
|
1,310
|
1,854
|
3,448
|
3,668
|
2,964
|
3,083
|
Capex / Sales
|
4.63%
|
5.66%
|
4.63%
|
6.5%
|
10.1%
|
8.53%
|
5.63%
|
4.96%
|
Announcement Date
|
1/30/20
|
1/29/21
|
2/3/22
|
2/2/23
|
2/6/24
|
-
|
-
|
-
|
Average target price
850.4
USD Spread / Average Target +10.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B | | -0.52% | 162B |
Other Pharmaceuticals
|